Filtered By:
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 60 results found since Jan 2013.
Evaluating how cationic lipid affects mRNA-LNP physical properties and biodistribution
Eur J Pharm Biopharm. 2023 Aug 12:S0939-6411(23)00205-9. doi: 10.1016/j.ejpb.2023.08.002. Online ahead of print.ABSTRACTRNA therapeutics represents a powerful strategy for diseases where other approaches have failed, especially given the recent successes of mRNA vaccines against the coronavirus disease 2019 (COVID-19) and small interfering (siRNA) therapeutics. However, further developments are still required to reduce toxicity, improve stability and biodistribution of mRNA-LNPs (lipid nanoparticles). Here, we show a rational combinatorial approach to select the best formulation based on a new cationic lipid molecule (IM21...
Source: European Journal of Pharmaceutics and Biopharmaceutics - August 14, 2023 Category: Drugs & Pharmacology Authors: Claire Gu éguen Thibaut Ben Chimol Margaux Briand Kassandra Renaud M élodie Seiler Morgane Ziesel Patrick Erbacher Malik Hellal Source Type: research
Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory virus that causes COVID-19 disease, with an estimated global mortality of approximately 2%. While global response strategies, which are predominantly reliant on regular vaccinations, have shifted from zero COVID to living with COVID, there is a distinct lack of broad-spectrum direct acting antiviral therapies that maintain efficacy across evolving SARS-CoV-2 variants of concern. This is of most concern for immunocompromised and immunosuppressed ...
Source: Antiviral Research - July 21, 2023 Category: Virology Authors: Ellen Bowden-Reid Scott Ledger Yuan Zhang Francesca Di Giallonardo Anupriya Aggarwal Alberto Ospina Stella Anouschka Akerman Vanessa Milogiannakis Gregory Walker William Rawlinson Stuart Turville Anthony D Kelleher Chantelle Ahlenstiel Source Type: research
Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors
Corona Virus Disease 2019 (COVID-19) continues to be a burden for human health since its outbreak in Wuhan, China in December 2019. Recently, the emergence of new variants of concerns (VOCs) is challenging for vaccines and drugs efficiency. In severe cases, SARS-CoV-2 provokes inappropriate hyperinflammatory immune responses leading to acute respiratory distress syndrome (ARDS) and even death. This process is regulated by inflammasomes which are activated after binding of the viral spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) receptor and triggers innate immune responses. Therefore, the formation of...
Source: Frontiers in cellular and infection microbiology - June 9, 2023 Category: Microbiology Source Type: research
Lipid nanoparticle-mediated drug delivery to the brain
Adv Drug Deliv Rev. 2023 May 5:114861. doi: 10.1016/j.addr.2023.114861. Online ahead of print.ABSTRACTLipid nanoparticles (LNPs) have revolutionized the field of drug delivery through their applications in siRNA delivery to the liver (Onpattro) and their use in the Pfizer-BioNTech and Moderna COVID-19 mRNA vaccines. While LNPs have been extensively studied for the delivery of RNA drugs to muscle and liver targets, their potential to deliver drugs to challenging tissue targets such as the brain remains underexplored. Multiple brain disorders currently lack safe and effective therapies and therefore repurposing LNPs could po...
Source: Advanced Drug Delivery Reviews - May 7, 2023 Category: Drugs & Pharmacology Authors: Purva Khare Sara X Edgecomb Christine M Hamadani Eden E L Tanner Devika S Manickam Source Type: research
Use of Iontophoresis Technology for Transdermal Delivery of a Minimal mRNA Vaccine as a Potential Melanoma Therapeutic
Biol Pharm Bull. 2023;46(2):301-308. doi: 10.1248/bpb.b22-00746.ABSTRACTmRNA vaccines have attracted considerable attention as a result of the 2019 coronavirus pandemic; however, challenges remain regarding use of mRNA vaccines, including insufficient delivery owing to the high molecular weights and high negative charges associated with mRNA. These characteristics of mRNA vaccines impair intracellular uptake and subsequent protein translation. In the current study, we prepared a minimal mRNA vaccine encoding a tumor associated antigen human gp10025-33 peptide (KVPRNQDWL), as a potential treatment for melanoma. Minimal mRNA...
Source: Biological and Pharmaceutical Bulletin - February 1, 2023 Category: Drugs & Pharmacology Authors: Rabab A Husseini Naoko Abe Tomoaki Hara Hiroshi Abe Kentaro Kogure Source Type: research
